The case for & against
Bull & Bear analysis
Bullish
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a biotechnology company specializing in the development of innovative RNA interference (RNAi) therapies targeting chronic diseases, with a strong focus on cardiovascular treatments. The company gained significant momentum with its lead product, plozasiran (Redempla), aimed at severe hypertriglyceridemia (SHTG). Having presented promising Phase 3 trial data, Arrowhead positions itself at the forefront of therapeutic advancements in lipid management, opening the door for substantial market penetration.
Bull says
- ↑Phase 3 plozasiran cut triglycerides 79–81% and reduced pancreatitis by 78%.
- ↑Q3 revenue reached $75M vs. $28M YoY; Redempla prescriptions doubled.
- ↑Cash reserves of $1.6B support R&D and expansion to 20k HCPs.
- ↑Priority review voucher can shorten FDA review from 10 to 6 months.
- ↑13 analysts rate Moderate Buy with an avg. price target of $98.42.
- ↑Strong momentum and liquidity factors signal stability amid volatility.
Bear says
- ↓Q3 net loss widened to $194.3M vs. $175.2M YoY; opex $245M.
- ↓Intense competition from Amgen, Ionis and others may hinder uptake.
- ↓sNDA approval timeline hinges on FDA pre-submission outcomes; delays probable.
- ↓Educating providers on SHTG is time-intensive and could delay adoption.
- ↓Weak profitability and growth factors indicate operational inefficiencies.
- ↓High sensitivity to interest rates and lack of favorable revisions risk momentum.
Investment themes with ARWR
Biotech↓ -1.57%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 11-26-2025neutral
Transcript signals
Bull points
- the big highlight for the clinical and regulatory teams was the submission and subsequent acceptance of our first new drug application, or NDA, by the U.S. FDA for investigational plus ASRAM for the treatment of familial chylomicronemia syndrome, or FCS.
- submit approval applications to additional global regulatory authorities in coming months for plasasteride for the treatment of patients with FCS.
- The clinical basis of the NDA submission is comprised of the findings in the Phase III Palisade study, which were positive, with supportive confirmatory evidence from the two from the Phase II clinical studies of the SUMMIT program.
Bear points
- If you take the patients that receive appropriate doses of statins and you add on to that PCSK9 inhibition, there is a persistent unmet medical need in patients that cannot get to goal inside of that HEFH market. there's no regulatory pathway to actually get at those patients other than just trying to do, you know, the full development program for HEFH, you know, frankly, probably to include a commitment for a CVOT. And we simply don't think the juice is worth the squeeze. if there were a way to, you know, to do a tailored program, you know, that focused on where the unmet medical need still is after PCSK9 addition to statins, that would be worth going after.
- our net loss for the quarter ended December 31, 2024, was $173.1 million, or $1.39 per share, which compares unfavorably to a net loss of $132.9 million, or $1.24 per share, for the quarter ended December 31, 2023.
- Revenue for the quarter ended December 31st, 2024 was 2.5 million compared to 3.6 million for the quarter ended December 31st, 2023.
Read full transcript analysis ›